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Abstract
Staphylococcus aureus, a pathogen responsible for hospital and community-acquired infections, expresses many virulence
factors under the control of numerous regulatory systems. Here we show that one of the small pathogenicity island RNAs,
named SprD, contributes significantly to causing disease in an animal model of infection. We have identified one of the
targets of SprD and our in vivo data demonstrate that SprD negatively regulates the expression of the Sbi immune-evasion
molecule, impairing both the adaptive and innate host immune responses. SprD interacts with the 59 part of the sbi mRNA
and structural mapping of SprD, its mRNA target, and the ‘SprD-mRNA’ duplex, in combination with mutational analysis,
reveals the molecular details of the regulation. It demonstrates that the accessible SprD central region interacts with the sbi
mRNA translational start site. We show by toeprint experiments that SprD prevents translation initiation of sbi mRNA by an
antisense mechanism. SprD is a small regulatory RNA required for S. aureus pathogenicity with an identified function,
although the mechanism of virulence control by the RNA is yet to be elucidated.
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Introduction
Staphylococcus aureus is a member of the commensal flora that can
be an opportunistic pathogen and a cause of nosocomial and
community-acquired infections [1]. With the widespread use of
antimicrobials, the incidence and spread of highly antibiotic-
resistant S. aureus strains have increased rapidly in recent years and
constitute a clinical and epidemiological challenge in hospitals all
over the world. In order to survive and to establish an infection, S.
aureus inhibits the attack of the host immune system, utilizing
diverse escape mechanisms [2]. The staphylococcal protein A
(SpA) recognizes the Fc domain of immunoglobulins which results
in inverted tagging and blocking the C1q and Fcc receptor
binding sites [3]. S. aureus IgG binding protein (Sbi) is another
immunoglobulin-binding protein expressed by S. aureus [4]. Sbi
acts also as a complement inhibitor and forms a tripartite complex
with host complement factors H and C3b [5].
S. aureus modulates the expression of virulence genes in response
to environmental changes thanks to global regulatory elements.
They are either two-component regulatory systems as the agr
(accessory gene regulator) regulon which is a sensor of the
population density [6], or transcription factors as the SarA family
of DNA binding-proteins [7]. These pathways allow the expression
of virulence factor regulation during host colonization and
dissemination. In addition to protein-mediated regulations,
ribonucleic acids also possess regulatory functions in many
bacterial pathogens [8]. Until now, RNAIII is the only S. aureus
regulatory RNA with a demonstrated function. It is the effector of
the global agr regulon that controls the synthesis of several
virulence factors [9,10]. RNAIII regulates the expression of
numerous mRNA targets at the translational and/or transcrip-
tional levels [11] and also acts as an mRNA, containing a small
ORF encoding the delta-hemolysin.
Additional regulatory RNAs are expressed by S. aureus [12–14].
Their expression profiles vary among clinical strains and many of
them, called Spr for ‘small pathogenicity island rNAs’, are
expressed from genomic pathogenicity islands containing virulence
and antibiotic resistance genes. Their functions are so far
unknown. This study was aimed at elucidating the role of one of
them, SprD. The Sbi immune evasion protein was identified as a
molecular target of SprD. We show that SprD interacts with the sbi
mRNA by an antisense mechanism, occluding the Shine-Dalgarno
(SD) sequence and the initiation codon. Moreover, we show that a
small regulatory RNA SprD has a major implication during the
intravenous (i.v.) infection of mice by a S. aureus clinical strain.
Results
SprD expression profile during growth
The expression of SprD was monitored during the growth of
N315 (agr2) [15,16] and MRSA252 (agr+) [17], two S. aureus
clinical isolates. SprD is already expressed during the early
exponential (E) phase (Figure 1), in contrast to RNAIII that is
transcribed at late exponential and stationary (S) growth phases.
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SprD expression increases during the E phase, up to the end of the
E phase for N315 and MRSA252 strains. To evaluate the
implications of the RNAIII in SprD expression during growth, an
RNAIII deletion mutant (DRNAIII) was constructed in strain RN1
(agr+) [18]. In contrast to N315 and MRSA252, the SprD
expression levels remain almost identical during cell growth in
strain RN1 (Figure 1C–D). Also, during growth SprD expression is
similar in RN1wt and in RN1-DRNAIII isogenic strains
(Figure 1C–D), suggesting that the expression pattern of SprD
is not influenced by the RNAIII. Therefore, the expression of
SprD is independent of the presence of absence of RNAIII.
SprD regulates the expression of an immune-evasion
protein at translational level
SprD is expressed from the genome of a converting phage
containing virulence factors [12]. In most S. aureus strains, sprD is
situated in-between scn and chp, within the 8 kb innate immune
evasion cluster (IEC) that contains the genes for modulation of the
early immune response. Such a genomic localization, as well as its
growth phase dependent expression, suggest that this RNA may
regulate the expression of virulence factor(s). In order to identify
the target(s) of SprD, we analyzed whether SprD modifies the
expression of extracellular proteins that contain many virulence
factors. For this purpose, a sprD deletion mutant (DsprD) was
constructed. We determined sprD 59-end by RACE (rapid
Author Summary
Bacteria possess numerous and diverse means of gene
regulation using RNA molecules, including small RNAs
(sRNAs). Here we show that one sRNA is essential for a
major human bacterial pathogen, Staphylococcus aureus,
to cause a disease in an animal model of infection. Our
study provides evidence that this RNA regulates the
expression of an immune evasion molecule secreted by
the bacterium to impair the host immune responses, and
we have solved the mechanism of the RNA-based
regulation at molecular level. So far, the mechanism of
bacterial virulence controlled by SprD is unrevealed, but
that small RNA has a huge impact in the course of a
bacterial infection. It implies possible new strategies in
fighting against that major human and animal bacterial
pathogen in preventing the expression of this regulatory
RNA.
Figure 1. SprD RNA expression profiles in several S. aureus strains. The expression of SprD during a 24-hour growth of S. aureus N315 (A),
MRSA252 (B), RN1 (C) and RN1 DRNAIII (D) strains by Northern blots using labeled DNA probes for SprD and for the RNAIII. As loading controls, the
blots were also probed for 5S rRNAs. The growth curves of N315 (A), MRSA252 (B), RN1(C) and RN1 DRNAIII (D) strains are presented, with the
quantification of the SprD levels in the four strains relative to the amount of 5S rRNAs from the same RNA extraction, the maximum value of SprD
expression for each strain was normalized to 100. (AU, arbitrary units).
doi:10.1371/journal.ppat.1000927.g001
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amplification of cDNA ends) at position C2007178 from the S.
aureus N315 sequence [16]. Based on (i) 59-end mapping, (ii)
transcript size derived from Northern blot analysis [12] and (iii)
transcription terminator prediction (Figure S1), sprD 39-end was
assigned at position G2007037, implying that SprD has 142 nts. In
S. aureus N315, the sprD gene was substituted for an erythromycin
resistance cassette by homologous recombination, abolishing the
SprD expression (Figure 2A). Complementation of DsprD was
achieved with a pCN38VsprD plasmid expressing SprD from its
endogenous promoter (strain DsprD+SprD). In S. aureus strains
RN4220 [19] and SH1000 [20] naturally lacking the sprD gene
(Figure 2A), SprD was expressed with the pCN38VsprD plasmid
(Figure 2A). In all three strains, levels of a ,45kD protein
decrease in the presence of SprD (Figure 2B). In the RN4220
strain, proteins from that band were eluted, a tryptic digest was
prepared and the fragments analyzed by MALDI-TOF mass
spectrometry. Twenty-five peptides were identified, all matching
the sequence of the Sbi protein (Table S1). A confirmation of the
decrease of the Sbi levels by SprD within the extracellular proteins
was obtained by monitoring the Sbi protein by Western blots
(Figure 2C). Interestingly, the SprD-dependent downregulation
of the Sbi protein was also observable within the intracellular
proteins (Figure 2C), indicating that the regulation does not affect
Sbi protein export but the overall Sbi protein expression levels.
Complementation of DsprD with the pCN38VsprD vector reduces
the Sbi protein levels in vivo (Figure 2, panels B and C),
demonstrating that SprD by itself regulates the expression of Sbi
protein. These results were also obtained in strain RN1 and its
isogenic DsprD mutant (data not shown).
Wild-type N315 and DsprD strains growth curves are superim-
posable in rich broth (Figure 2D), demonstrating that the SprD
does not influence S. aureus proliferation. The complemented strain
leads to lower Sbi protein levels compared to the wild-type N315
strain (Figure 2, panels B and C) because the expression of SprD
from pCN38VsprD is higher than its endogenous expression levels
in wild-type N315 strain (Figure 2A). In the N315 strain, the
highest expression of the Sbi protein during growth is at mid-
exponential phase and goes to zero at early stationary phase and
beyond (Figure 2D). In its isogenic DsprD mutant, the Sbi protein
levels are higher during growth but the expression profile remains
similar (Figure 2D). Taken together, these data establish a
functional link between the Sbi protein levels and the expression of
SprD demonstrating that, in different S. aureus genetic back-
grounds, SprD represses Sbi expression in vivo.
To test whether the regulation of Sbi by SprD is at
transcriptional and/or at translational level(s), the sbi mRNA
Figure 2. The SprD regulates expression of the Sbi protein at translational level in vivo. (A) Northern blot analysis of the SprD expression
at the E phase (OD600nm: 2) in wild-type N315 (WT), N315 isogenic DsprD mutant (D),DsprD transformed by pCN38VsprD (complemented strain
‘DSprD’) and also in strains RN4220 and SH1000 transformed by pCN38VsprD. (B) Coomassie staining of SDS–PAGE of the exoproteins in N315,
RN4220 and SH1000 strains expressing, or not, SprD at the E phase (OD600nm: 2). The arrows point to the reduced levels of a protein when SprD is
expressed. (C) Immunoblot analysis with anti-Sbi antibodies of extra- and intracellular proteins in the three S. aureus strains at the E phase (OD600nm:
2). (D) Monitoring the expression of the Sbi protein during S. aureus growth in strains N315 (WT) and DsprD (D) by immunoblots with anti-Sbi
antibodies separated on the same gel. The graph shows the quantification of the Sbi protein levels in both strains relative to the total protein amount
(Figure S5). The blue squares represent the DsprD and the red triangles represent WT. The superimposable growth curves of the two strains are
represented as the dashed lines. (E) Northern blot analysis of the sbi mRNA in wild-type N315 (WT) and DsprD mutant (D) during bacterial growth. 16S
rRNAs are loading controls. The graph shows the quantification of the sbi mRNA levels in both strains relative to 16S rRNA and the colours correspond
to panel D. We have measured the sbi mRNA half-life in WT SH1000 strain using rifampicin treatment, which is about 1 min (data not shown).
doi:10.1371/journal.ppat.1000927.g002
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levels were monitored by Northern blots in wt N315 and DsprD
strains. The sbi mRNA expression profiles are similar in both
strains (Figure 2E), with a gradual increase of the mRNA
expression up to the early-exponential phase and a sharp decrease
to basal levels later on. When the sbi mRNA strongly decreases at
the stationary phase, SprD is not more expressed, indicating that
the Sbi repression at the S phase is ‘SprD-independent’. Also, the
sbi mRNA expression profile does not follow the protein synthesis
pattern, probably meaning that the Sbi protein is stable and
accumulates during growth. Therefore, in strain N315, the
expression of the Sbi protein is dictated by its transcription profile
during bacterial growth. In addition, SprD does not modify the
steady state level of the sbi mRNA. Taken together, these results
show that SprD downregulates Sbi expression at translational
level.
SprD interacts with the sbi mRNA by an antisense
mechanism
We focused our next investigations on Sbi to elucidate the
mechanism of its regulation by SprD. A substantial fraction of
bacterial regulatory RNAs for which a function was identified
interacts with target mRNAs to regulate gene expression [21].
Putative interactions between SprD and the 59-portion of sbi
mRNA were detected in silico (Figure 3A). We first determined
the sbi mRNA transcriptional start site by RACE at position
G2476039 from the N315 genomic sequence [16]. Therefore, sbi
mRNA 59-end is located 41 nts upstream of the AUG initiation
codon (Figure 3A). Duplex formation between SprD and a
179 nts-long sbi mRNA fragment containing its 59 UTR sequence
followed by 46 codons was analyzed by gel retardation assays. A
‘SprD-sbi mRNA’ duplex was detected at a 1:4 molar ratio and
nearly all sbi mRNA was in complex with SprD at a 1:20 molar
ratio (Figure 3B). The binding is specific since a 100- to 2,000-
fold molar excess of total tRNAs do not displace the sbi mRNA
from a preformed ‘SprD-sbi mRNA’ complex. A sbi mRNA
deletion mutant lacking 61 nts at its 59-end (sbiD61, Figure 3A,
brackets), predicted to be part of the interaction, does not bind
SprD (Figure 3B), demonstrating that these nucleotides are
required to interact with SprD. Reciprocally, the deletion of 36
nucleotides (U35 to U70) from SprD (SprDD36, Figure 3A,
brackets) abolishes complex formation (Figure 3B), showing that
these nucleotides are also required for the ‘SprD-sbi mRNA’
interaction.
To provide a direct evidence in vivo of the interaction between
SprD and the sbimRNA, we have expressed the SprDD36 RNA in
the DsprD strain. Western blots indicate that SprDD36 RNA is
unable to dowregulate the Sbi protein levels in vivo, in contrast to
full-length SprD (Figure 3C). Northern blot indicates that the
SprDD36 mutant RNA is expressed at similar levels than SprD wt,
demonstrating that the absence of Sbi downregulation by the
SprDD36 mutant RNA is not due to its instability in vivo.
Therefore, this result is a strong evidence of a direct interaction
between SprD and the sbi mRNA in vivo, as illustrated in
Figure 3A. The interaction between the sbi mRNA and SprD
forms in vitro without the contribution of a helper molecule
Figure 3. The regulation of Sbi by SprD involves a direct interaction between SprD and the sbi mRNA. (A) In silico prediction of an
interaction between SprD and the sbi mRNA. The free energy of the SprD-sbi mRNA pairing is provided. The nucleotides bordered by two brackets
were deleted in SprDD36 and in sbiD61. In the sbi mRNA sequence, the grey nucleotides are the putative SD (59-GAAAGGG-39) and the start codon.
(B) Complex formation between SprD and the sbi mRNA. Native gel retardation assays of purified labeled sbi mRNAs (the sbi mRNA contains 179 nts
at the mRNA 59-end and sbiD61 contains 118 nts) with increasing amounts of either unlabeled SprD, mutant SprD lacking nts 35–70 (SprDD36) or of a
100 to 2000-fold excess of unlabeled yeast total tRNAs. (C) Monitoring in vivo the expression levels of the Sbi protein in strain N315 DsprD (2)
complemented by either pCN38VsprD (+SprD), or by pCN38VsprDD36 (+SprDD36) at E phase. Bottom panel: Northern blot analysis of SprDD36 and
SprD RNAs, 5S rRNAs are the loading controls. (D) Monitoring the expression levels of the Sbi protein in the RN4220 WT and RN4220 Dhfq isogenic
strains, in the presence and absence of the SprD, by immunoblots with anti-Sbi antibodies.
doi:10.1371/journal.ppat.1000927.g003
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(Figure 3B), as the Sm-like Hfq protein. To test the contribution
of the Hfq protein in vivo, we have monitored the SprD-mediated
regulation of Sbi in an hfq deletion strain versus an isogenic wild-
type strain. As shown in Figure 3D, the in vivo regulation of Sbi
expression by SprD takes place independently of the presence or
absence of Hfq. These results demonstrate that SprD forms a
stable complex with the sbi mRNA in vitro and in vivo, as well as
deletions altering the complementarities between the two RNAs
impair complex formation.
The ribosome binding site of the sbi mRNA is
sequestered by SprD
Next, we analyzed in detail complex formation between SprD
and the sbi mRNA. As a prerequisite to this study, conformations
of the free SprD (nt 1–142) and of the 59-sbi mRNA (nt 1–179)
were investigated using chemical and enzymatic probes. Both
transcripts were end-labeled and their solution structures were
probed by RNase V1, which cleaves double-stranded (ds) RNAs or
stacked nucleotides, and by nuclease S1 and lead, which both
cleave accessible single-stranded (ss) RNAs. The reactivity toward
these structural probes were monitored for each nucleotide
(Figure S2 for SprD and Figure S3 for the 59-sbi mRNA).
The data are summarized onto SprD and sbi mRNA 59-end
models that they support (Figure 4A). Out of the 142 nts of SprD,
96 are involved in intramolecular pairings, implying structural
stability. SprD has two folded ends (H1 and H3–H4) flanking a
54 nt-long accessible domain made of an unstable stem (H2)
capped by a loop (L2), bordered by two ss (H1/H2 and H2/H3)
junctions. For the 59-end of the sbi mRNA, the data support the
existence of two folded stem-loops (S1-B1 and S2-B2) flanking a
Figure 4. Structural analysis of the ‘SprD-sbi mRNA’ duplex indicates that SprD binds to the sbi mRNA ribosome binding site. (A)
Secondary structures of the SprD RNA and of the sbi mRNA 59-end (nts 1–62) from S. aureus N315 based on structural probes in solution that supports
each of the proposed structures. Triangles are V1 cuts; arrows capped by a circle are S1 cuts; uncapped arrows are lead cuts. Intensities of cuts and
cleavages are proportional to the darkness of the symbols. Structural domains are indicated. The AUG and putative SD sequence are squared on the
sbi 59-end mRNA structure. On the secondary structure models of two isolated RNAs, the nucleotides involved in the structural changes induced by
the formation of the ‘SprD-sbi mRNA’ duplex have been circled. (B) Conformational changes of SprD induced by complex formation with the sbi
mRNA detected by structural probes. Autoradiograms of cleavage products of 59-labeled SprD by RNases S1 and V1 in the presence (+) or absence
(2) of sbi mRNA. Lanes C, incubation controls; lanes GL, RNase T1 hydrolysis ladder; lanes AL, RNase U2 hydrolysis ladder. The RNA sequence is
indexed on the right side. (C) Conformational changes of the sbi mRNA 59-end induced by complex formation with SprD monitored by structural
probes. Indications are as for panel A. (D) Pairing interactions between SprD and the sbi mRNA 59-end, based on (i) computer prediction, (ii) native
gel retardation assays and mutational analyses, (iii) structural mapping of the conformation of SprD in complex with the sbi mRNA 59-end and (iv)
structural mapping of the conformation of the sbi mRNA 59-end in complex with SprD. Only the structural information concerning the conformation
of the duplex is indicated, using similar signs as for panel A. The plus (+) and minus (2) signs indicate respectively the appearance or the
disappearance of cleavages by the structural probes when the two RNAs are in duplex.
doi:10.1371/journal.ppat.1000927.g004
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9 nt-long accessible domain (S1/S2 junction) that contains the
predicted SD (Shine-Dalgarno) sequence. The AUG initiation
codon is located in loop B2.
The pairing prediction and structural changes induced by
complex formation between the two RNAs were examined by
subjecting a ‘SprD-sbi mRNA’ complex to statistical nuclease S1
and RNases V1 cleavages. Binding of sbi mRNA induced structural
changes in a restricted region of SprD (from U21 to G76), covering
theH1/H2 junction,H2, L2, and theH2/H3 junction (Figure 4B).
The structural data that supports the interaction within each helix,
as drawn in Figure 4D, are the following: in the presence of the sbi
mRNA, S1 cleavages at U23–U30 (H1/H2 junction and H2), U37-
G39 and U60–U61 (H2), U46–U47 (loop L2) and A69-U70 (H2/
H3 junction) disappeared within the SprD structure, whereas S1
cuts at G51-A54 (H2) appear. Upon duplex formation, V1 cuts
appeared at A32 (H2) and at U45–U46 (L2). The binding of SprD
led to correlated structural changes in 59-end of sbimRNA (fromG1
to G62, Figure 4C), encompassing the predicted SD and AUG
initiation codon. In the ‘sbi mRNA-SprD’ duplex, S1 cleavages
appeared at positions A53-C59 (S2) and disappeared at positions
U43-A48 (B2) within the sbimRNA sequence. Also, RNAse V1 cuts
at positions A16 and U50-A52 appeared, supporting the complex
formation as drawn at Figure 4D.
Therefore, these data are consistent with the deletion analysis of
the ‘SprD-sbi mRNA’ complex and support a bipartite helical
interaction between the two RNAs (Figure 4D). Structural
probing of the RNA duplex indicates that a discontinuous helical
domain forms between the two RNAs (22–48SprD/28–53sbi mRNA
involving the SD and AUG codon and 56–75SprD/1–19sbi mRNA).
This helical domain is interrupted by an accessible ss RNA (49–
55SprD/22–27sbi mRNA). Nucleotides from the sbi mRNA flanking
the interaction domain (54–59sbi mRNA) become heavily cleaved by
nuclease S1 due to steric constraints from the neighbouring
duplex. These data demonstrate that the interaction between
SprD and the sbi mRNA involves it’s predicted SD sequence and
AUG initiation codon.
The ‘sbi mRNA-SprD’ pairing prevents ribosome loading
and translation initiation
Since the interaction of SprD with the sbi mRNA coincides with
the region of mRNAs covered by the ribosomes during translation
initiation [22], SprD should prevent ribosome loading on the sbi
mRNA. To test this, toeprint assays were performed on ternary
initiation complexes including purified 70S ribosomes, initiator
tRNAfMet and the sbi mRNA. Two ribosome toeprints were
detected onto the sbi mRNA, at 15 and 17 nts downstream from
the initiation codon respectively (Figure 5A, lane 4), supporting
the location of the sbi mRNA start codon as drawn on Figure 4.
SprD reduced ribosome loading onto the sbi mRNA in a
concentration-dependent manner (Figure 5A, lanes 5–7). In-
creasing amounts of SprDD36, that cannot form a complex with
the sbi mRNA (Figure 5B), did not prevent ribosome loading
onto the sbi mRNA (Figure 5A, lanes 8–10). It is concluded that
SprD inhibits sbi mRNA translation by preventing ribosome
binding by antisense pairings with the sbi mRNA 59-end. These
results are in agreement with data obtained in vivo, showing that
SprD inhibits Sbi expression at translational level.
SprD enhances the virulence of S. aureus
Since one SprD target is the Sbi immune-evasion molecule that
was proposed to be involved in S. aureus pathogenicity [4,5], this
RNA may play (a) role(s) during staphylococcal infections. This
suggestion is in agreement with its co-location with virulence
factors [12]. Therefore, we tested the importance of the SprD
RNA during staphylococcal infections on an animal infection
model. Using a murine i.v. sepsis model with an inoculum of 109 S.
aureus per mouse, we showed that the virulence of the DsprD
mutant is abolished (100% survival at day 21 of infection), whereas
all animals infected with the parental wild-type strain die
(Figure 6A). The virulence of the trans-complemented
DsprD+SprD strain is partially restored as compared to the wild
type (50% survival at day 21, P,0.02). In a different i.v. infection
experiment with a 56108 CFU inoculum per mouse in which
animals were sacrificed at day 6, the kidneys of mice inoculated
with the DsprD mutant are small and homogenous red-brown,
whereas those of mice inoculated with the wild-type strain are
substantially swollen and displayed mottled discoloration suggest-
ing numerous abscesses (Figure 6B). Kidneys of mice infected
with the DsprD+SprD strain are slightly less swollen than the latter,
but display homogenous discoloration with no distinct abscesses
(Figure 6B). Results of the macroscopic observation are
confirmed in the same experiment by viable bacteria counts, as
Figure 5. SprD prevents ribosome loading and translation initiation onto the sbimRNA. (A) Ribosome toeprints onto the sbi mRNA. ‘+/2’
indicates the presence of purified ribosomes with SprD (lanes 2 and 5–7) or with SprDD36 (lanes 3 and 8–10). Concentrations of SprD and SprDD36
were 0.4 mM (lanes 5 and 8), 2 mM (lanes 6 and 9) and 10 mM (lanes 7 and 10). The experimentally-determined toeprints are indicated with arrows. U,
A, G and C refer to the sbi mRNA sequencing ladders. (B) Schematic view of the antisense regulatory mechanism of SprD with the sbi mRNA 59-end.
SprD is proposed to recognize its target mRNA via a ‘loop–single strand’ interaction (green) that extends further upstream and downstream.
doi:10.1371/journal.ppat.1000927.g005
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the mean kidney titres (6 SD) were 7.260.3, 4.961.0, 8.560.6
log10 CFU per pair of kidneys for the wild-type, DsprD, and
DsprD+SprD strains, respectively (Figure 6C). After 6 days of
infection, the in vivo persistence of plasmid pCN38VsprD in the
DsprD+SprD strain was verified in 160 randomly selected colonies
obtained from kidney homogenates. All of them have retained
resistance to chloramphenicol, a specific marker of pCN38. The
virulence defect of a SprD-deletion strain, compared to an isogenic
wild-type strain, was also observed in the agr positive RN1 strain
(data not shown). Altogether, these results demonstrate the
importance of SprD during bacterial infections triggered by S.
aureus clinical isolates. Using the same murine i.v. sepsis model, we
also tested the implications of Sbi in S. aureus virulence. For this
purpose, a sbi deletion strain (Dsbi) and a strain overexpressing sbi
under its endogenous promoter from the pCN35Vsbi plasmid (sbi+)
were constructed (Figure panels S6A and S6B). We showed
that the virulence of the two Dsbi and sbi+ mutants is similar to that
of the isogenic wild-type strains (Figure S6C). These results
indicate that only varying the expression levels of the Sbi protein is
insufficient to account for the SprD virulence phenotype in our
animal infection model and imply that SprD has additional
target(s) involved in staphylococcal virulence. Taken together, our
findings indicate that SprD plays a major role in the virulence of S.
aureus.
Discussion
In this report, we show that a small regulatory RNA expressed
by S. aureus clinical strains plays an essential role in bacterial
virulence during the infection of mice in a model of septicaemia.
After RNAIII, SprD is the second regulatory RNA that plays a
major role in S. aureus virulence. RNAs are emerging as regulators
that enable bacterial pathogens to express virulence genes when
required during infection, illustrating their essential roles in
pathogenesis [23]. Numerous sRNAs are implicated in the
infections caused by Gram-positive and negative bacteria [23].
Some sRNAs are expressed from pathogenicity islands [12], and
such horizontally acquired post-transcriptional regulators can
regulate the expression of genes encoded by the core genome
[24 and this report]. Some sRNAs regulate the expression of
virulence factors [10] or are expressed when bacteria multiplies
within mammalian cells [25]. Their implication in bacterial
pathogenesis, however, was not demonstrated in animal models of
infection. Recent studies have shown that several sRNAs expressed
from various bacteria including V. cholerae, L. monocytogenes and S.
typhimurium modulate or are involved in virulence on mice infection
models [26–28].
In S. aureus, RNAIII is the paradigm for RNA-controlled
expression of virulence genes, being the effector of the agr system.
RNAIII was the first RNA shown to be involved in bacterial
pathogenesis more than fifteen years ago [9] and is the only
example in S. aureus until now. Compared to the 142 nt-long
SprD, the RNAIII (514 nt-long) is almost four times bigger,
encodes a small protein, has a complex structure made of 14 stem-
loops [29] and regulates the expression of several virulence genes
[10]. The importance of agr for virulence in animal models has
been reported [30–31], but the exact contribution of RNAIII
awaits the experimental testing of an RNAIII deletion strain.
This report reveals that a small regulatory RNA expressed by S.
aureus, SprD, enhances the virulence of the agr negative N315
clinical strain (Figure 6) and of the agr positive RN1 strain (data
not shown). All the mice infected with the S. aureus strain that does
not express SprD survive three weeks after the inoculation,
whereas all mice challenged with the wild type strain expressing
SprD die within 16 days following inoculation. The virulence of
the trans-complemented strain is half restored, with the mice
kidneys containing viable bacteria as for the wild type strain. The
partial restoration of the virulence of the complemented strain
could be due to partial plasmid loss after day 6 or, on the other
Figure 6. The SprD RNA enhances the virulence of a S. aureus
clinical isolate on infected mice. (A) Survival of mice infected with
S. aureus wild-type strain N315 (black square), its isogenic DsprD mutant
(black circle) and DsprD mutant complemented with pCN38VsprD
(black triangle). Groups of 10 eight-week old Swiss mice were
inoculated i.v. with 109 bacteria and monitored daily for 3 weeks. (B)
Macroscopic aspect of kidneys after i.v. infection with S. aureus wild-
type strain N315 (WT), isogenic DsprD mutant (D) and DsprD mutant
complemented with pCN38VsprD (D+SprD). Increased size, discolor-
ation and multiple abscesses (black arrow) caused by the wild-type
strain was not observed with the DsprD mutant, while the DsprD
complemented strain yielded diffuse discoloration instead of focal
abscesses (white arrow). Eight-week old Swiss mice were inoculated
with ca. 1.56108 bacteria and sacrificed after six days. (C) Recovery of S.
aureus strains from the kidneys of infected mice six days after bacterial
challenge. Groups of 5 mice were inoculated i.v. with ca. 1.56108 CFU of
wild-type strain N315, DsprD mutant and DsprD mutant complemented
with pCN38VsprD, respectively. Each individual animal is indicated by a
circle symbol with mean bacterial titres represented as a line.
doi:10.1371/journal.ppat.1000927.g006
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hand, to a negative impact on bacterial virulence of the higher
expression of SprD from the plasmid, compared to the wild type
strain. The macroscopic aspect of kidneys from mice infected with
bacteria expressing, or not, SprD as well as the lower amounts of
bacteria detected in the infected kidneys when SprD is not
expressed, indicate that this RNA plays a major role in the
virulence of S. aureus (Figure 6). The effect of SprD on virulence
might be linked to the lower amount of bacteria detected in the
infected kidneys in the absence of the RNA.
We tested the ability of SprD to modify gene expression in S.
aureus cells and identified the immune evasion Sbi protein as one
molecular target of the RNA. The Sbi protein is among the most
abundant secreted proteins [32] produced by many S. aureus
clinical isolates [4,33]. We have unravelled the mechanism by
which SprD regulates Sbi expression. The action of SprD on the
sbi mRNA proceeds by antisense pairings, blocking translation
initiation. The pairing interaction between SprD and the sbi
mRNA and its functional outcome is presented as a model in
Figure 5B. A central domain of SprD pairs with the sbi mRNA
59-end that includes its SD sequence and AUG initiation codon,
blocking translation initiation. For SprD, all the structural changes
induced by the formation of the duplex are located in stem-loop
H2 and single-stranded flanking domains H1/H2 and H2/H3.
The pairings between SprD and the sbi mRNA could be divided
into three interacting domains that include the very 59-end of the
sbi mRNA, its SD sequence and its AUG initiation codon. The
interacting domains that are single-strand in each of the two RNA
structures probably pair first (the H2/H3 junctionSprD with B1sbi,
L2SprD with the purine-rich S1/S2 junctionsbi and the H1/H2
junctionSprD with B2sbi), followed by spreading through their
respective secondary structures. In vitro and in vivo, experimental
evidences demonstrate that the regulation of Sbi expression by
SprD takes place without the need of the Hfq protein, illustrating
the facultative requirement of the Hfq protein for sRNA–mRNA
duplex formation among bacteria. The ‘SprD-sbi mRNA’
interaction involves 41 base-pairs and, as suggested [34], extended
pairings probably overcome the requirement for the Hfq RNA
chaperone.
This strategy of gene expression inhibition is frequently used by
bacterial regulatory RNAs [reviewed in 21], including the
downregulation of another IgG binding protein, SpA, by the
RNAIII [35]. Translation inhibition by regulatory RNAs in
bacteria is usually sufficient for gene silencing and can occur in the
absence of mRNA destabilization [36]. If target mRNA
degradation is triggered, as with the double-strand specific RNAse
III in some RNA-mediated gene regulations in S. aureus [35], the
process of gene silencing becomes irreversible. SprD does not
affect the sbi mRNA levels, indicating that this gene regulation
could be reversible.
In this report, we demonstrate that Sbi is directly regulated by
SprD in vivo and in vitro and we also show that this SprD-mediated
regulation is agr independent. Indeed, it was previously reported
that the inactivation of the agr global virulence regulator increases
the abundance of Sbi in vivo [32], indicating that agr, as SprD, is a
negative regulator of Sbi expression. We show that SprD regulates
the expression of the Sbi protein in both agr positive (SH1000,
RN4220 and RN1) and agr negative (N315) strains, demonstrating
that the SprD-mediated regulation of Sbi occurs independently of
agr. In addition, in various clinical strains, Sbi expression is
induced by human IgGs [37] although the mechanism of such a
positive regulation is currently unknown, but is independent of the
RNAIII (data not shown). IgGs increase the levels of the Sbi
protein in the presence and absence of SprD (Figure S4),
indicating that the two regulations are independent. Hence, the
Sbi expression is monitored by at least three regulatory pathways,
suggesting that the amount of Sbi has to be precisely controlled in
S. aureus cells. Such a sophisticated regulation network implies that
this protein should be an important factor for staphylococcal
physiology.
The Sbi protein interferes with innate immune recognition by
binding multiple host proteins including the complement factors H
and C3 as well as IgG (the Sbi protein traps human IgGs [4]) and
b2-glycoprotein I [5,38,39], suggesting that Sbi has a role during
staphylococcal infections. Analysis of the virulence of sbi deletion
and overexpression strains suggests that Sbi does not appear to be
a major virulence factor for staphylococcal infection in a model of
septicaemia. Similarly to SpA, the first discovered staphylococcal
immunoglobulin-binding protein which has properties comparable
to those of Sbi [40], its contribution to bacterial virulence was
difficult to prove in vivo, demonstrating the variability of the results
obtained depending on the animal model considered [41–43]. As
for SpA, the effect of Sbi on virulence is probably hard to be
identified, only visible in a few infection models. Since the Sbi
protein is predicted to be implicated at early stages of the infection,
its contribution is difficult to assess in our infection model.
Moreover, the Sbi and SpA proteins could have overlapping
functions in host immune evasion, deregulation of expression of
either sbi or spa may be insufficient to induce virulence defects on
animal models. The sbi deletion or the Sbi overproduction have no
detectable virulence phenotypes in our infection model, indicating
that the virulence defect of the sprD deletion mutant is not caused
only by the deregulation of the Sbi expression levels. Thus, SprD is
predicted to have other target(s) and/or more general functions
implicated in staphylococcal virulence. We do not exclude,
however, the implication of Sbi in S. aureus virulence.
The expression profile of SprD during growth shows elevated
expression levels at stationary phase (Figure 1) when the sbimRNA
levels are sparse (Figure 2E), implying that SprD functions are not
restricted to the regulation of Sbi expression, also suggesting that
SprD has additional target(s) that could be involved at various times
during the infection. Indeed, RNAs often regulate the expression of
more than a single target, as for several E. coli RNAs [reviewed in
44] and for the S. aureus RNAIII [11]. Also, it would not be so
surprising that regulatory RNA(s) other than SprD act synergisti-
cally to regulate the expression of the sbi mRNA during cell growth,
and a reasonable candidate could be the RNAIII. As for SprD that
regulates the expression of Sbi and of other putative target(s), the
RNAIII represses, by antisense pairings, the expression of the Sbi-
like SpA protein and also controls the expression of additional genes
either directly or by limiting the expression of the Rot transcrip-
tional regulator [11]. Preliminary data obtained in our laboratory
indicate that SprD has at least one mRNA target in S. aureus cells.
The identification of SprD additional target(s) and learning how
they are regulated by SprD will be required to understand
implication of this sRNA in S. aureus virulence. Identification of
Sbi as the first target of SprD is an important step in elucidating the
complete gene network regulated by this small RNA which has such
a major role in virulence.
Our work, in combination with what is known about RNAIII,
suggests a major role for regulatory RNAs in S. aureus
pathogenicity. This study also illustrates how sophisticated the
regulations of virulence factors productions are during S. aureus
infections. It reinforces the roles of RNAs in regulating numerous
biological processes in this bacterium. Further studies will be
necessary to identify the complete gene network regulated by
SprD, its additional target(s), why SprD has such an important role
in staphylococcal virulence and the underlying mechanisms of
regulations.
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Materials and Methods
Strains and plasmids
Strains and plasmids are listed in Table S2. S. aureus trains were
cultured at 37uC in brain heart infusion broth (BHI, Oxoid).
When necessary, chloramphenicol and erythromycin were used at
a 10 mg/ml concentration. In pCN38VsprD and pCN35VsprD
sprD is expressed from its own promoter. The sprD sequence with
40 nts upstream and 35 nts downstream was amplified from N315
genomic DNA as a 217-bp fragment, with flanking PstI and EcoRI
sites. The PCR product was cloned in pCN38 [45] and pCN35
[45]. For producing the pCN38VsprDD36, mutagenized oligonu-
cleotides ‘T7sprD_delfor’ and ‘T7sprD_delre’ were used (Table
S3). In pCN35Vsbi, sbi is expressed from its endogenous promoter.
The sbi sequence was PCR amplified from N315 genomic DNA as
a 1700-bp fragment with flanking PstI and EcoRI restriction sites.
Construction of the deletion strains
To inactivate the sprD gene, DNA fragments of 1000 bp
upstream and 800 bp downstream of sprD were amplified by PCR
from genomic DNA and cloned together with the ermB from pCN51
[45] into XbaI-EcoRI sites of temperature-sensitive plasmid pBT2
[46]. Primers used for cloning are indicated in Table S3. The
resulting plasmid pBT2DsprD was transformed into S. aureus strain
RN4220 and then into S. aureus N315 to achieve integration of the
ermB gene into the genome by homologous recombination. Mutants
were enriched by cultivation at 42uC. Cells from the stationary-
phase culture were plated on TSA plates and incubated at 37uC.
Colonies were imprinted on plates supplemented with 10 mg/mL
chloramphenicol. Chloramphenicol-sensitive colonies were tested
by PCR for replacement of sprD for the erythromycin cassette. The
deletion of sprD was confirmed by Northern blot (Figure 2A).
Inactivations of the sbi and RNAIII genes were performed by the
samemethod except that no resistance marker was inserted between
their 59 and 39 DNA sequences. The primers used for constructing
pBT2Dsbi and pBT2DRNAII are shown in Table S3.
Animal infection model
Virulence levels of the SprD+ strain N315, its isogenic mutant
DsprD and complemented strain DsprD pCN38VsprD were
compared using a murine intravenous sepsis model. Groups of
10 female Swiss mice, 6- to 8-weeks old (Charles River
Laboratories, L’Arbresle, France) were inoculated i.v. with
300 mL of bacterial suspensions containing 109 S. aureus cells in
0.9% NaCl. The survival of the mice was monitored for 21 days,
and the statistical significance of differences between groups was
evaluated using the Mann-Whitney U test. A P value of,0.05 was
considered significant. With the same three strains, 3 groups of 5
female Swiss mice, 6- to 8-weeks old (Charles River Laboratories)
were then infected i.v. with 56109 bacteria. Six days after
inoculation, the mice were euthanized with CO2 and their kidneys
excised. After photographs were taken, the organs were homog-
enized, diluted in 0.9% NaCl and plated on 5% blood agar for
determination of bacterial titres, expressed as log10 CFU per pair
of kidneys. Morphology observation included swelling, discolor-
ation and presence of macroscopic abscesses. The stability of
plasmid pCN38VsprD (encoding chloramphenicol resistance) in
the complemented DsprD mutant was assessed by plating randomly
selected colonies grown from kidney homogenates on nutrient agar
with containing 20 mg/mL chloramphenicol.
Protein isolation, mass spectrometry and immunoblots
For the preparation of protein extracts, bacteria are grown until
the exponential or stationary phases and the cells are pelleted for
10 min at 4uC (8.000g). For purifying the extracellular proteins,
the supernatants are collected, filtered (0.45 mm sterilized filter)
and precipitated with 10% trichloroacetic acid. The precipitates
are washed with ice-cold acetone and loaded onto SDS-PAGE
according to [47]. For the total protein extractions, pellets of 2-ml
cultures are washed with TE (50 mM EDTA, 50 mM Tris
pH 7.5), and suspended in 0.2 ml of the same buffer containing
0.1 mg/ml lysostaphin. Following incubation at 37uC for 10 min,
samples are boiled for 5 min, analyzed by SDS-PAGE and stained
by Coomassie blue R-250. The proteins of interest are extracted
from gel, trypsin digested and the peptides identified by MALDI
MS/MS and RP-HPLC/NanoLC/ESI-MS-MS. For the immu-
noblots, proteins are transferred to PVDF membrane (Immobilon-
P, Millipore). Signals are visualized using a STORM 840
Phosphor-Imager (Molecular Dynamics) and quantified using
Image-QuantNT 5.2.
RNA isolation, Northern blots, 59- RACE, transcription and
RNA labeling
Total RNAs are prepared as described [48]. For SprD and
other sRNAs, Northerns are performed with 5 mg of total RNAs,
as described [12]. For sbi mRNA, Northerns are performed as
described [49]. RACE assays are carried out according to 49 with
the primers from Table S3. Wild-type and mutant RNAs for
probing, gel-shift assays or toeprints are transcribed from PCR
fragments generated from genomic DNA with the primers from
Table S3. For producing the template-encoding SprDD36,
mutagenized oligonucleotides (Table S3) were used. The RNAs
were produced by in vitro transcription using MEGAscript
(Ambion). Adding [a32-P]UTP within the transcription mix
produces radioactive transcripts. 59-RNA labeling is performed
as described [49]. The RNAs are purified by 8% PAGE, eluted,
ethanol precipitated and stored at 280uC.
Gel-shift assays and RNA probing
Gel retardation assays are performed as described [49],
0.4 pmol of labeled wt or sbiD61 mRNAs are incubated with
various concentrations (from 1.6 to 20 pmols) of unlabeled wt
SprD or SprDD36. For structural analysis duplexes between sbi
mRNA and SprD are prepared by incubating 0.4 pmol of labeled
RNA and 1.6 pmol of unlabeled RNA in a buffer containing
10mM Tris-HCl (pH 7,5), 60 mM NaCl, 10mM EDTA and
5 mM DTT for 15 min at 25uC. Structural assays are performed
as described [49]. Digestions are at 25uC for 15 min with 2.5 mg of
yeast tRNAs with 0.2 or 1 unit of S1 and 1024 or 5.1025 units of
V1. Lead(II) cleavages are performed with 0.2 or 0.4 mM PbAc in
25 mM Hepes (pH 7.5), 7 mM Mg acetate and 35 mM K acetate
for 10 min at 25uC. The reactions are precipitated, the pellets
dissolved in loading buffer (Ambion). The samples are denatured
for 5 min at 65uC prior to separation on 8% polyacrylamide/8M
urea gels. Gels are dried and visualized (STORM 840 Phosphor-
Imager).
Toeprints
The toeprints are as described [50] with modifications.
Annealing mixtures contain 0.2 pmol of sbi mRNA and 1 pmol
of labeled ‘SBIrevTR’ primer in a buffer containing 10 mM Tris-
acetate (pH 7.5), 60 mM NH4Cl, and 1 mM DTT. For the assays
in the presence of SprD, various concentrations of wt or SprDD36
are added prior to the purified E. coli 70S ribosomes. The
ribosomes are reactivated for 15 min at 37uC and diluted in the
reaction buffer in the presence of 1 mM MgCl2. 4 pmols of 70S
are added in each assay, incubated for 5 min and MgCl2 is
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adjusted to 10 mM. After 5 min, 10 pmols of uncharged
tRNAfMet are added and incubated for 15 min. cDNA is
synthesized with 2 UI of AMV RT (Biolabs) for 15 min. Reactions
are ended by 10 ml of loading buffer II (Ambion). The cDNAs are
loaded and separated onto 8% PAGE. The toeprints are located
on the sbi mRNA sequence by sequencing the DNA.
Ethics statement
All animal experiments were performed in accordance to
European guidelines and recommendation of the French Agricul-
tural Office for the care of animals subjects. Experiments were
carried out in the accredited research animal facility of Institut
Pasteur de Lille (accreditation number, A59107). All animal
protocols were approved by the locally appointed investigational
review board (Institut Pasteur de Lille, accreditation number,
A59107).
List of accession numbers of genes and proteins
mentioned in the text
S. aureus Immunoglobulin G binding protein A : GenBank ID:
BAB41326.1
S. aureus Sbi protein: Genbank ID: AF027155
S. aureus RNAIII (nt 1260 to 1571): GenBank accession number:
X52543
S. aureus Hfq: PDB code 1Kq1A
Supporting Information
Figure S1 Sequence alignments of SprD from several S. aureus
strains. The bolded nucleotides are the 59-ends derived from N315
RACE mapping and the underlined nucleotides are the sequence
variations. The stars are the sequence identities. SprD has a 9-
base pair helix (H4) ending by a U6 stretch, acting as a
transcription terminator.
Found at: doi:10.1371/journal.ppat.1000927.s001 (0.06 MB
DOC)
Figure S2 Monitoring of SprD conformation by structural
probes. SprD conformation was probed by RNase V1, that cleaves
double-strands (ds) or stacked nucleotides and by nuclease S1 and
lead that both cleave accessible single-strands (ss). Autoradiograms
of cleavage products of 59-labeled SprD by lead, nucleases S1 (0.2
or 1 unit) and V1 (1024 or 5.1025 unit) from long (left) and short
(right) runs. Lanes C, incubation controls; Lanes GL, RNAse T1
hydrolysis ladders; lanes AL, RNAse U2 hydrolysis ladder; lanes
AH, alkaline hydrolysis ladders. The sequence is indexed at the
right side. The reactivity toward these probes was monitored for
each nucleotide. Ds-specific cuts at U28–U30, G39–C40, A54,
A62–A64, U79–U80, A89, G91 and A125–A127 and the absence
of nuclease S1 and lead cleavages at G1-U8, G14-U21, C40–C42,
G49-C52, G76-U92, U101–U109, G113-U119, G121-U129 and
G134-C142 indicate that four RNA helices (H1–H4) form
(Fig. 1A). Helix H2 can be extended from 4 to 13 base-pairs,
but its lower portion is cut by both ss- (U28-G39, G55-A64) and
ds- (U28–U30, A62–A64) probes, implying instability and
breathing. S1 cuts at U9-G13, U44-C48, A95-U100, C132-
G133 and lead cuts at A11–A12, U46-C48 and U94 support loops
L1–L4. Based on S1 and lead cleavages and no V1 cuts, U22–U27
and U65-C75 fold as an ss RNA. Lead cuts at U110–U112
support an internal bulge within H3.
Found at: doi:10.1371/journal.ppat.1000927.s002 (2.84 MB
DOC)
Figure S3 Monitoring the conformation of the sbi mRNA 59-end
(179 nts) by structural probes. Autoradiograms of cleavage
products of 59-labeled sbi mRNA by RNase V1, nuclease S1 and
lead. For the details, please refer to Figure S3 legend.
Found at: doi:10.1371/journal.ppat.1000927.s003 (6.50 MB
DOC)
Figure S4 Human IgGs from serum increase Sbi protein levels
in the presence (+) and absence (2) of SprD. Immunoblot analysis
with anti-Sbi antibodies of total intracellular proteins in S. aureus
SH1000 strain in the presence (+) or absence (2) of 10% human
serum.
Found at: doi:10.1371/journal.ppat.1000927.s004 (0.05 MB
DOC)
Figure S5 Coomassie staining of the samples presented on Fig. 2,
panels B and C (A) and on Fig. 2D (B) indicates that identical
amounts of proteins were loaded for strains ‘wt’, ‘D’ and D+sprD’.
Found at: doi:10.1371/journal.ppat.1000927.s005 (0.52 MB
DOC)
Figure S6 Deleting or overproducing the Sbi protein have no
detectable effect on the virulence of the N315 S. aureus clinical
isolate on infected mice. Monitoring the expression of the Sbi
protein in strains N315 Dsbi (A) and in the sbi overproducing
strain pCN35-sbi (B), compared to a strain carrying the empty
plasmid vector (pCN35) and to the wild-type strain (wt) by
immunoblots with anti-Sbi antibodies. (C) Survival of mice
infected with S. aureus wild-type strain N315 (square), its isogenic
Dsbi mutant (circle) and wild-type strain transformed with
pCN35Vsbi (triange). Groups of 5 seven-week old Swiss mice
were inoculated i.v. with 2.109 bacteria and monitored daily for 2
weeks.
Found at: doi:10.1371/journal.ppat.1000927.s006 (2.48 MB
DOC)
Table S1 MS identification of the Sbi protein by detecting 25
Sbi peptides.
Found at: doi:10.1371/journal.ppat.1000927.s007 (0.06 MB
DOC)
Table S2 Strains and plasmids used in this study.
Found at: doi:10.1371/journal.ppat.1000927.s008 (0.05 MB
DOC)
Table S3 DNA primers used in this study.
Found at: doi:10.1371/journal.ppat.1000927.s009 (0.08 MB
DOC)
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